LY86 and cardiac hypertrophy: Specifically, MD1 was downregulated in the hearts from patients with hypertrophic cardiomyopathy, whereas cardiac-specific overexpression of MD1 in mice exerted protective effects against obesity- or pressure overload-induced cardiac hypertrophy.